Physician profile
Sandeep Randhawa
NPI 1841486172
$94,240.01
in general payments reported to CMS, 2019-2025
20 companies · $36K in 2025
The $36K reported for 2025 was more than what 96% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $11K · 2021: $3,042 · 2022: $8,999 · 2023: $16K · 2024: $19K · 2025: $36K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Food and Beverage: $5,869 · Consulting Fee: $5,420 · Travel and Lodging: $491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,010.84 |
| Food and Beverage | $5,868.64 |
| Consulting Fee | $5,420.00 |
| Travel and Lodging | $490.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $83,693.52 | 2019-2025 | Eylea Hd, Eylea |
| Alimera Sciences, INC. | $5,148.88 | 2019-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $2,849.82 | 2024-2025 | Izervay |
| Genentech USA, INC. | $528.34 | 2019-2025 | Vabysmo, Susvimo |
| Abbvie INC. | $386.71 | 2022-2025 | |
| Regeneron Pharmaceuticals, INC. | $249.97 | 2019-2024 | Eylea Hd |
| Novartis Pharmaceuticals Corporation | $220.35 | 2019-2020 | |
| Abiomed | $216.65 | 2025 | |
| Ani Pharmaceuticals, INC. | $194.07 | 2024-2025 | Purified Cortrophin Gel, Yutiq, Iluvien |
| Mallinckrodt Enterprises LLC | $187.60 | 2019 | |
| Bausch & Lomb Americas INC. | $159.77 | 2023-2025 | Xipere, Visudyne |
| Biogen, INC. | $148.06 | 2022-2024 | Byooviz |
| Genentech, INC. | $72.75 | 2024 | Vabysmo |
| Alcon Vision LLC | $55.46 | 2019 | |
| Allergan, INC. | $48.31 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $26.22 | 2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.64 | 2020 | |
| Eyepoint US, INC. | $16.28 | 2022 | |
| Harrow Eye, LLC | $15.61 | 2023 | Iheezo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Randhawa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.